decitabine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
nucleosides antiviral or antineoplastic agents, cytarabine or azacitidine derivatives 790 2353-33-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • decitabine mesylate
  • decitabine mesilate
  • decitabine
  • dacogen
An azacitidine derivative and antineoplastic antimetabolite. It inhibits DNA methyltransferase to re-activate silent genes, limiting METASTASIS and NEOPLASM DRUG RESISTANCE. Decitabine is used in the treatment of MYELODISPLASTIC SYNDROMES, and ACUTE MYELOID LEUKEMIA.
  • Molecular weight: 228.21
  • Formula: C8H12N4O4
  • CLOGP: -1.90
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 3
  • TPSA: 120.74
  • ALOGS: -1.62
  • ROTB: 2

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 4.87 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 4.60 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 130 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 1 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.58 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 10 mg/mL Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Bocci G, Oprea TI, Benet LZ

Approvals:

DateAgencyCompanyOrphan
May 2, 2006 FDA Astex Pharmaceuticals, Inc.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 369.34 28.96 163 3385 118286 63367188
Neutropenia 98.62 28.96 80 3468 174925 63310549
Myelosuppression 94.44 28.96 39 3509 23664 63461810
Pancytopenia 92.56 28.96 61 3487 96872 63388602
Bone marrow failure 89.69 28.96 40 3508 29250 63456224
Pneumonia 89.41 28.96 118 3430 456649 63028825
Thrombocytopenia 78.60 28.96 66 3482 151091 63334383
Acute myeloid leukaemia 74.39 28.96 30 3518 17117 63468357
Acute myeloid leukaemia recurrent 66.89 28.96 16 3532 1607 63483867
Off label use 63.65 28.96 125 3423 674337 62811137
Disease progression 60.48 28.96 52 3496 122706 63362768
Product use in unapproved indication 59.64 28.96 61 3487 179019 63306455
Sepsis 52.49 28.96 53 3495 153070 63332404
Pyrexia 43.93 28.96 87 3461 470391 63015083
Haematotoxicity 42.72 28.96 17 3531 9359 63476115
Death 39.53 28.96 73 3475 374308 63111166
Splenic abscess 39.27 28.96 7 3541 162 63485312
Respiratory failure 36.22 28.96 36 3512 101822 63383652
Acute myeloid leukaemia refractory 35.42 28.96 6 3542 102 63485372
Leukaemia recurrent 34.20 28.96 9 3539 1329 63484145
Escherichia bacteraemia 32.42 28.96 11 3537 3872 63481602
Pneumonia fungal 32.40 28.96 12 3536 5443 63480031
Myelodysplastic syndrome 30.38 28.96 16 3532 16738 63468736
Neutrophil count decreased 29.99 28.96 25 3523 56381 63429093
Posterior reversible encephalopathy syndrome 29.86 28.96 16 3532 17329 63468145

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 326.76 25.21 221 5070 136628 34815012
Acute myeloid leukaemia 137.05 25.21 63 5228 18207 34933433
Neutropenia 117.64 25.21 131 5160 156647 34794993
Off label use 99.49 25.21 204 5087 419320 34532320
Bone marrow failure 93.34 25.21 57 5234 29196 34922444
Pancytopenia 88.02 25.21 89 5202 95068 34856572
Myelosuppression 86.76 25.21 47 5244 19218 34932422
Infection 85.86 25.21 86 5205 90829 34860811
Pneumonia 76.06 25.21 168 5123 362459 34589181
Thrombocytopenia 71.32 25.21 102 5189 156145 34795495
Sepsis 67.76 25.21 103 5188 166458 34785182
Acute myeloid leukaemia recurrent 66.69 25.21 21 5270 2149 34949491
Bacteraemia 56.73 25.21 36 5255 19681 34931959
Acute myeloid leukaemia refractory 54.75 25.21 9 5282 41 34951599
Product use in unapproved indication 48.16 25.21 73 5218 117426 34834214
Aspergillus infection 41.93 25.21 25 5266 12229 34939411
Pyrexia 41.33 25.21 127 5164 332886 34618754
Cytopenia 41.07 25.21 25 5266 12698 34938942
Disease progression 39.88 25.21 64 5227 108013 34843627
Platelet count decreased 35.08 25.21 64 5227 119653 34831987
Therapy partial responder 28.75 25.21 18 5273 9598 34942042
Sinusitis fungal 28.22 25.21 8 5283 570 34951070
Mucormycosis 28.13 25.21 15 5276 5927 34945713
Respiratory failure 28.02 25.21 55 5236 108517 34843123
Anaemia 27.92 25.21 88 5203 233247 34718393
Drug ineffective 26.98 25.21 138 5153 456613 34495027
Therapy non-responder 26.28 25.21 31 5260 39115 34912525
Septal panniculitis 26.24 25.21 5 5286 59 34951581
Haematotoxicity 26.18 25.21 16 5275 8178 34943462
Choroidal effusion 25.98 25.21 6 5285 187 34951453

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 661.01 25.35 365 7887 230634 79505502
Neutropenia 186.05 25.35 186 8066 287524 79448612
Bone marrow failure 182.28 25.35 94 8158 51013 79685123
Pneumonia 177.48 25.35 274 7978 659972 79076164
Acute myeloid leukaemia 174.73 25.35 78 8174 30807 79705329
Myelosuppression 169.80 25.35 83 8169 40213 79695923
Acute myeloid leukaemia recurrent 164.33 25.35 43 8209 3340 79732796
Product use in unapproved indication 142.04 25.35 151 8101 250208 79485928
Pancytopenia 137.16 25.35 123 8129 165622 79570514
Thrombocytopenia 133.11 25.35 150 8102 265109 79471027
Sepsis 124.46 25.35 146 8106 269282 79466854
Off label use 99.40 25.35 259 7993 906956 78829180
Haematotoxicity 87.10 25.35 39 8213 15480 79720656
Disease progression 83.48 25.35 99 8153 184263 79551873
Infection 82.89 25.35 113 8139 241599 79494537
Acute myeloid leukaemia refractory 73.93 25.35 13 8239 144 79735992
Bacteraemia 72.20 25.35 44 8208 32780 79703356
Pyrexia 64.24 25.35 184 8068 678525 79057611
Aspergillus infection 59.04 25.35 32 8220 19129 79717007
Leukaemia recurrent 52.69 25.35 17 8235 2757 79733379
Respiratory failure 52.25 25.35 78 8174 180833 79555303
Cytopenia 46.55 25.35 28 8224 20355 79715781
Platelet count decreased 45.25 25.35 76 8176 194588 79541548
Anaemia 44.25 25.35 123 8129 444892 79291244
Pneumonia fungal 43.92 25.35 22 8230 11188 79724948
Therapy partial responder 37.42 25.35 23 8229 17374 79718762
Mucormycosis 37.30 25.35 18 8234 8451 79727685
Therapy non-responder 34.38 25.35 45 8207 92260 79643876
Gene mutation 33.47 25.35 12 8240 2674 79733462
Cardiac failure 32.74 25.35 58 8194 154784 79581352
Escherichia bacteraemia 32.12 25.35 15 8237 6547 79729589
Chronic graft versus host disease 31.65 25.35 15 8237 6766 79729370
Septic shock 31.28 25.35 50 8202 122751 79613385
Septal panniculitis 30.26 25.35 6 8246 132 79736004
Malignant neoplasm progression 28.82 25.35 51 8201 135939 79600197
Drug ineffective 27.97 25.35 199 8053 1080714 78655422
Graft versus host disease 27.65 25.35 18 8234 15008 79721128
Splenic abscess 26.19 25.35 7 8245 589 79735547
Headache 25.97 25.35 18 8234 653754 79082382
Delayed engraftment 25.78 25.35 6 8246 286 79735850
Allogenic stem cell transplantation 25.72 25.35 5 8247 99 79736037
Bronchopulmonary aspergillosis 25.52 25.35 20 8232 22274 79713862

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01BC08 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
ANTIMETABOLITES
Pyrimidine analogues
FDA MoA N0000000233 Nucleic Acid Synthesis Inhibitors
MeSH PA D000963 Antimetabolites
MeSH PA D000964 Antimetabolites, Antineoplastic
MeSH PA D000970 Antineoplastic Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D009676 Noxae
FDA EPC N0000175595 Nucleoside Metabolic Inhibitor

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Acute myeloid leukemia, disease indication 91861009
Myelodysplastic syndrome indication 109995007
Diabetes mellitus contraindication 73211009 DOID:9351
Kidney disease contraindication 90708001 DOID:557
Disease of liver contraindication 235856003 DOID:409
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Breastfeeding (mother) contraindication 413712001




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 12.94 acidic
pKa2 13.68 acidic
pKa3 4.39 Basic
pKa4 2.93 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
100MG;35MG INQOVI OTSUKA N212576 July 7, 2020 RX TABLET ORAL 8618075 Oct. 16, 2028 METHOD FOR INHIBITING CYTIDINE DEAMINASE BY ADMINISTERING CEDAZURIDINE
100MG;35MG INQOVI OTSUKA N212576 July 7, 2020 RX TABLET ORAL 8618075 Oct. 16, 2028 METHOD FOR INHIBITING DEGRADATION OF A CDA SUBSTRATE BY ADMINISTERING CEDAZURIDINE
100MG;35MG INQOVI OTSUKA N212576 July 7, 2020 RX TABLET ORAL 8268800 Aug. 22, 2030 METHOD FOR INHIBITING CYTIDINE DEAMINASE BY ADMINISTERING CEDAZURIDINE
100MG;35MG INQOVI OTSUKA N212576 July 7, 2020 RX TABLET ORAL 8268800 Aug. 22, 2030 METHOD FOR INHIBITING DEGRADATION OF A CDA SUBSTRATE BY ADMINISTERING CEDAZURIDINE
100MG;35MG INQOVI OTSUKA N212576 July 7, 2020 RX TABLET ORAL 8268800 Aug. 22, 2030 TREATMENT OF CHRONIC MYELOMONOCYTIC LEUKEMIA
100MG;35MG INQOVI OTSUKA N212576 July 7, 2020 RX TABLET ORAL 8268800 Aug. 22, 2030 TREATMENT OF MYELODYSPLASTIC SYNDROME

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
100MG;35MG INQOVI OTSUKA N212576 July 7, 2020 RX TABLET ORAL July 7, 2025 NEW CHEMICAL ENTITY
100MG;35MG INQOVI OTSUKA N212576 July 7, 2020 RX TABLET ORAL July 7, 2027 TREATMENT OF ADULT PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS), INCLUDING PREVIOUSLY TREATED AND UNTREATED, DE NOVO AND SECONDARY MDS WITH THE FOLLOWING FRENCH-AMERICAN-BRITISH SUBTYPES (REFRACTORY ANEMIA, REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS, REFRACTORY ANEMIA WITH EXCESS BLASTS, AND CHRONIC MYELOMONOCYTIC LEUKEMIA [CMML]) AND INTERMEDIATE-1, INTERMEDIATE-2, AND HIGH-RISK INTERNATIONAL PROGNOSTIC SCORING SYSTEM GROUPS.

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
DNA (cytosine-5)-methyltransferase 1 Enzyme INHIBITOR IC50 7.52 CHEMBL CHEMBL
DNA (cytosine-5)-methyltransferase 3A Enzyme INHIBITOR CHEMBL CHEMBL

External reference:

IDSource
4025438 VUID
N0000179023 NUI
D03665 KEGG_DRUG
879492-57-6 SECONDARY_CAS_RN
15657 RXNORM
4025438 VANDF
C0049065 UMLSCUI
CHEBI:50131 CHEBI
CHEMBL1201129 ChEMBL_ID
DB01262 DRUGBANK_ID
D000077209 MESH_DESCRIPTOR_UI
451668 PUBCHEM_CID
6805 IUPHAR_LIGAND_ID
6374 INN_ID
776B62CQ27 UNII
203877 MMSL
21366 MMSL
81707 MMSL
d05788 MMSL
011499 NDDF
420517007 SNOMEDCT_US
420759005 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
decitabine HUMAN PRESCRIPTION DRUG LABEL 1 0143-9385 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS ANDA 28 sections
Decitabine Human Prescription Drug Label 1 0781-3296 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS ANDA 27 sections
Decitabine HUMAN PRESCRIPTION DRUG LABEL 1 16714-749 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS ANDA 25 sections
Decitabine HUMAN PRESCRIPTION DRUG LABEL 1 16714-928 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS ANDA 27 sections
Decitabine HUMAN PRESCRIPTION DRUG LABEL 1 16729-224 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS ANDA 27 sections
Decitabine HUMAN PRESCRIPTION DRUG LABEL 1 16729-224 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS ANDA 27 sections
decitabine HUMAN PRESCRIPTION DRUG LABEL 1 25021-231 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS ANDA 28 sections
decitabine HUMAN PRESCRIPTION DRUG LABEL 1 25021-231 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS ANDA 28 sections
Decitabine HUMAN PRESCRIPTION DRUG LABEL 1 43598-348 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS ANDA 27 sections
Decitabine HUMAN PRESCRIPTION DRUG LABEL 1 43598-427 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS ANDA 27 sections
DECITABINE HUMAN PRESCRIPTION DRUG LABEL 1 50742-430 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS ANDA 24 sections
DECITABINE HUMAN PRESCRIPTION DRUG LABEL 1 50742-430 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS ANDA 24 sections
Decitabine HUMAN PRESCRIPTION DRUG LABEL 1 55111-556 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS ANDA 27 sections
Decitabine Human Prescription Drug Label 1 55150-376 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS ANDA 27 sections
Decitabine Human Prescription Drug Label 1 55150-376 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS ANDA 27 sections
Decitabine Human Prescription Drug Label 1 55150-376 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS ANDA 27 sections
Dacogen HUMAN PRESCRIPTION DRUG LABEL 1 59148-046 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS NDA 30 sections
Decitabine HUMAN PRESCRIPTION DRUG LABEL 1 63323-825 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS ANDA 27 sections
Decitabine HUMAN PRESCRIPTION DRUG LABEL 1 64679-067 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS ANDA 24 sections
INQOVI HUMAN PRESCRIPTION DRUG LABEL 2 64842-0727 TABLET, FILM COATED 35 mg ORAL NDA 31 sections
INQOVI HUMAN PRESCRIPTION DRUG LABEL 2 64842-0727 TABLET, FILM COATED 35 mg ORAL NDA 31 sections
Decitabine HUMAN PRESCRIPTION DRUG LABEL 1 67184-0535 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS ANDA 28 sections
Decitabine HUMAN PRESCRIPTION DRUG LABEL 1 67457-316 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS ANDA 27 sections
Decitabine HUMAN PRESCRIPTION DRUG LABEL 1 68001-422 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS ANDA 27 sections
DECITABINE HUMAN PRESCRIPTION DRUG LABEL 1 68001-573 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS ANDA 25 sections
decitabine Human Prescription Drug Label 1 68083-528 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS ANDA 27 sections
decitabine HUMAN PRESCRIPTION DRUG LABEL 1 68180-738 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS ANDA 25 sections
Decitabine HUMAN PRESCRIPTION DRUG LABEL 1 69097-285 INJECTION 50 mg INTRAVENOUS ANDA 24 sections
Decitabine HUMAN PRESCRIPTION DRUG LABEL 1 69097-905 INJECTION 50 mg INTRAVENOUS ANDA 21 sections
Decitabine HUMAN PRESCRIPTION DRUG LABEL 1 69097-905 INJECTION 50 mg INTRAVENOUS ANDA 21 sections